Neuropathology Core
神经病理学核心
基本信息
- 批准号:10643933
- 负责人:
- 金额:$ 23.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAddressAlzheimer&aposs DiseaseAlzheimer&aposs disease related dementiaAnimal ModelAutopsyBiological MarkersBlood VesselsBrainCell LineCell modelClinicalCollaborationsCollectionCommunitiesDataDementiaDiagnosisDiagnosticEducation and OutreachEnrollmentEvaluationFamilyHealth ProfessionalHeterogeneityImageImpaired cognitionInternationalInterventionMeasuresMethodsMolecularNerve DegenerationNeurodegenerative DisordersParticipantPathogenesisPathologyPatientsProceduresPropertyProteomicsProtocols documentationReportingResearchResearch PersonnelResourcesRiskSamplingSourceStandardizationSyndromeSystemTechnologyTherapeuticTissue SampleTissuesTrainingWorkbrain tissuedisease heterogeneityinduced pluripotent stem cellinnovationlaboratory facilitymild cognitive impairmentneuroimagingneuropathologynew therapeutic targetnext generationnormal agingnovelnovel diagnosticsnovel therapeutic interventionpreventprogramspsychosocialrepositoryresearch clinical testingtherapeutically effectivetissue processing
项目摘要
ABSTRACT- NEUROPATHOLOGY CORE
The Neuropathology (NP) Core provides for diagnostic neuropathological evaluations of: 1) patients and control
subjects enrolled in the Clinical Core (CC), and 2) other clinically well documented patients with
neurodegenerative disease. The NP Core aims to enhance understanding of the heterogeneity of AD/ADRD
to develop better biomarkers and discover novel and effective therapeutic approaches that promote progress
towards achieving the NAPA research implementation milestones. The protocols used by the NP Core will
be state of the art and consistent with 21st century brain banking procedures. These will be essential to meet the
increasingly sophisticated needs of the AD research community. We will emphasize delineating the presence of
overlapping neurodegenerative syndromes. In this renewal, we will continue to emphasize the central theme of
the NYU ADRC: elucidating the clinico-pathological substrates that underlie the transitions between normal
aging, subjective cognitive decline (SCD), MCI, and dementia to help develop novel interventions that delay or
prevent these transitions. The overall objectives of the NP Core of the NYULH ADRC are to provide staff,
technical resources, laboratory facilities, and expertise to investigate the structural and molecular properties of
the brains of both patients with ADRC and those of normal controls. Aims 1–3 of the NP core encompass the
key neuropathology functions of the NP Core. Aims 4 and 5 will develop innovative neuropathological
technologies. The emerging clinical evaluation system of ATN—which is proposed to underlie transitional stages
between normal aging to SCD, SCD to MCI, and MCI to early dementia—needs to be correlated with
comprehensive neuropathological measures that also reflect disease heterogeneity. In addition, while brain
tissue is an essential resource, it cannot be developed into dynamic cellular models. Hence, the NP Core has
launched a new induced pluripotent stem cell (iPSC) program, providing investigators with an easily replenished
source of tissue to address key questions about the heterogeneous pathogenesis of AD/ADRC. Aims 6 and 7
focus on using NP Core resources to train the next generation of neuropathologists and translational
neuroscientists conducting research on AD/ADRD, support their studies to develop novel therapeutic targets,
and promote educational outreach about brain and biospecimen donation. The combination of these aims will
help the NP Core to develop better biomarkers and to discover novel effective, therapeutic approaches; hence,
accelerating progress towards achieving the NAPA research implementation milestones.
摘要-神经病理学核心
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THOMAS M WISNIEWSKI其他文献
THOMAS M WISNIEWSKI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THOMAS M WISNIEWSKI', 18)}}的其他基金
Novel Approaches to Understand the Pathogenesis and Treat Alzheimer's Disease
了解发病机制和治疗阿尔茨海默病的新方法
- 批准号:
10621825 - 财政年份:2020
- 资助金额:
$ 23.17万 - 项目类别:
Novel Approaches to Understand the Pathogenesis and Treat Alzheimer's Disease
了解发病机制和治疗阿尔茨海默病的新方法
- 批准号:
10428579 - 财政年份:2020
- 资助金额:
$ 23.17万 - 项目类别:
Blocking the binding of Aβ and apoE as a novel therapeutic approach for AD
阻断 Aβ 和 apoE 的结合作为 AD 的新型治疗方法
- 批准号:
10428585 - 财政年份:2020
- 资助金额:
$ 23.17万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 23.17万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 23.17万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 23.17万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 23.17万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 23.17万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 23.17万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 23.17万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 23.17万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 23.17万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 23.17万 - 项目类别:
Research Grant














{{item.name}}会员




